Philadelphia University + Thomas Jefferson University

Den, Robert

< Back

Profile

Robert B. Den, MD

Robert B. Den, MD

Contact Dr. Den

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6702
(215) 955-0412 fax

Research & Clinical Interests

I am a board-certified radiation oncologist who specializes in the treatment of prostate cancer. I see patients and discuss their cases in a genitourinary multidisciplinary clinic with colleagues in urology and medical oncology. I specialize in using IMRT to treat men with prostate cancer to improve patients outcomes and decrease the side effects of treatment. 

I am also a translational researcher with a laboratory at Jefferson that focuses on combining new biologic agents with radiation therapy. The goal of this work is to introduce the most exciting compounds into clinical trials to benefit my patients.

Publications

Most Recent Peer-Reviewed Publications

  1. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup
  2. Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy
  3. The role of genomic techniques in predicting response to radiation therapy
  4. Increasing faculty participation in resident education and providing cost-effective self-assessment module credit to faculty through resident-generated didactics
  5. Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model
  6. Individual patient-level meta-Analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease
  7. Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes
  8. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality
  9. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer
  10. siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K-ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer
  11. MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2
  12. RB loss promotes prostate cancer metastasis
  13. Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: Exploratory analysis from 12,076 patients
  14. Prognostic outlier genes for enhanced prostate cancer treatment
  15. Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer
  16. Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies
  17. Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential
  18. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer
  19. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer
  20. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy—A Multi-Institutional Observational Study